Assessment, Targets, Thresholds and Treatment Bryan Williams NICE clinical guideline 127.

Slides:



Advertisements
Similar presentations
The Seventh Report of the Joint National Committee on the Prevention, Detection, Evaluation, and Treatment of High Blood Pressure Internal Medicine/Pediatrics.
Advertisements

JNC 8 Guidelines….
National Institute for Health and Clinical Excellence.
Update on hypertension - diagnosis, monitoring and guideline treatment targets Prof. Richard McManus, Birmingham, United Kingdom.
ASCOT TRIAL Abbas Zaidi 20/09/05. Hypertension is one of the most prevalent risk factors for cardiovascular disease, affecting as many as 800 million.
The British Approach to Antihypertensive Therapy: Guidelines from the National Institute of Health and Clinical Excellence Power Over Pressure
Stanford Prevention Research Center STANFORD SCHOOL OF MEDICINE National Trends in the Prescribing of Anti-Hypertensive Medications Jun Ma, MD, PhD Research.
Hypertension Diagnosis and Treatment  Based on JNC 7 – published in 2003  Goal: BP
Managing hypertension in primary care
BHS Guidelines for the management of hypertension BHS IV, 2004 and Update of the NICE Hypertension Guideline, 2006 Guidelines for management of hypertension:
Canadian Diabetes Association Clinical Practice Guidelines Treatment of Hypertension Chapter 25 Richard E. Gilbert, Doreen Rabi, Pierre LaRochelle, Lawrence.
Blood Pressure Monitoring
Hypertension Nick Price Aim Consider the application of ‘evidence based practice’ in the management of hypertension in primary care. EBP – defined.
Hypertension.
Ben Selph Mercer COPHS, Class of 2012 SEGA Geriatrics NICE Guidelines for Hypertension.
Pharmacological Treatment of Hypertension Update 2012.
HYPERTENSION NMP. How Common? 25% UK adults 25% UK adults > 50% adults over 60 > 50% adults over 60.
Implementing NICE guidance
Hypertension Guideline
HOME AND AMBULATORY BLOOD PRESSURE MONITORING
NICE Guideline Synopsis. Definitions Stage 1 Hypertension Clinic BP 140/90 or higher And ABPM Daytime average/HBPM 135/85 or higher.
DR. IDOWU AKOLADE EDM DIVISION LUTH
1 1 Individualized Therapy forHypertension Introduction to Primary Care: a course of the Center of Post Graduate Studies in FM PO Box – Riyadh
Selection of Antihypertensive Drug. BP ClassificationSystolic BP, mm Hg Diastolic BP, mm Hg Normal
1 Hypertension Overview. 2 Leading Risks For Death (World Health Organization 2002) Cholesterol Alcohol HYPERTENSION Tobacco use Overweight.
Hypertension In elderly population. JNC VII BP Classification SBP mmHgDBP mmHg Normal
NICE GUIDELINES HYPERTENSION Masroor Syed. Latest Issue June 2006 Evidence Based uickrefguide.pdf
DION GALLANT, MD PRIMARY CARE SERVICE LINE MEDICAL DIRECTOR PRESBYTERIAN MEDICAL GROUP JNC 8.
Investigations: Urine examination. Urine examination. Serum K. Serum K. Serum creatinine. Serum creatinine. Blood Sugar. Blood Sugar. Hb. Hb.
Hypertension NICE CG127 August Hypertension is not a disease it is a risk factor for cardiovasuclar disease (CVD)-it is a modifiable risk factor.
10 Points to Remember on An Effective Approach to High Blood Pressure ControlAn Effective Approach to High Blood Pressure Control Summary Prepared by Debabrata.
Hypertension: Blood Pressure Measurement and the new NICE guideline Prof Richard McManus BHS Annual Meeting Cambridge 2011 NICE clinical guideline 127.
Hypertension Dr Nidhi Bhargava 8/10/13. Why Treat Increased risk of cardiovascular death and mortality Increased systolic, diastolic and pulse pressures.
Primary care team meeting Hypertension Dr Som Desilva.
Case Report and Lit Review: Reduction of Proteinuria in Diabetic Nephropathy with Spironolactone Harry W. Floyd, M.D. Family Medicine Kingstree, South.
Thiazide-Like/Calcium Channel Blocker (CCB) Agents: A Major Combination for Hypertension Management Safar M, Blacher J. Am J Cardiovasc Drugs. 2014; DOI.
7/27/2006 Outcomes in Hypertensive Black and Nonblack Patients Treated with Chlorthalidone, Amlodipine, and Lisinopril* * Wright JT, Dunn JK, Cutler JA.
Hypertension Family Medicine Specialist CME October 15-17, 2012 Pakse.
HYPERTENSION RECOMMENDATIONS FOR FOLLOW UP BASED ON INITIAL BP READING
PHARMACOTHERAPY OF HYPERTENSION Based on New Guidelines Fariborz Nikaeen; MD Interventional cardiologist 2 november 2015.
Objective: To asses the efficacy of hydrochlorothiazide on 24-h blood pressure (BP) control.Methods: Review of all the randomized trials that assessed.
Pre-ALLHAT Drug Use IMS Health NDTI, Year % of Treated Patients on Medication CCBs Beta Blockers Diuretics ACE Inhibitors.
NICE/BHS Hypertension Guideline Review 28 June 2006 John Barker ESH Clinical Hypertension Specialists European Society of Hypertension Specialist Accreditation.
CCB in Management of Hypertension in Older Persons Presented by Mona Ahmed sherif Marwa Shaaban Shimaa Adel Ahmed Salma Sadek Alia khalid.
1 ALLHAT Antihypertensive Trial Results by Baseline Diabetic Status January 28, 2004.
Dr.AZDAKI (cardiologist).   Initial monotherapy is successful in many patients with mild primary hypertension (formerly called "essential" hypertension).
CR-1 Candesartan in HF Benefit/Risk James B. Young, MD Cleveland Clinic Foundation.
MACROVASCULAR COMPLICATIONS, DYSLIPIDEMIA and HYPERTENSION 2003 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada.
Treatment of Hypertension in Adults With Diabetes DR AMAL HARFOUSH.
HEART FAILURE. Excellent Care 1. Diagnosis 2. ACE-I and B blocker 3. Aldosterone antagonist 4. Exercise 5. Statin and aspirin if CVD 6. Digoxin with AF.
HF diagnosis: audit of NTproBNP uptake and outcomes across Sheffield An update on diagnosis and management of HF Dr Abdallah Al-Mohammad, MD, FRCP(Edin),
Managing Blood Pressure in the Older Adult Jamie McCarrell, Pharm.D., BCPS, CGP TTUHSC School of Pharmacy.
Hypertension in primary care
Clinical Management of primary hypertension
Hypertension In The Stroke Patient
David Antecol, M.D., FACC, FASH, FRCP(C) Specialist in Clinical Hypertension (American Society of Hypertension) Disclosures: None.
Diagnosis and initial management of hypertension in primary care
JNC VIII Hypertension.
Hypertension JNC VIII Guidelines.
Defining hypertension
Hypertension treatment guidelines from the United Kingdom’s National Institute for Health and Care Excellence. Guidelines identify angiotensin-converting.
Drugs for Hypertension
Primary Efficacy End Point.
Recommendations for the treatment of confirmed hypertension in people with diabetes. *An ACE inhibitor (ACEi) or ARB is suggested to treat hypertension.
Table of Contents Why Do We Treat Hypertension? Recommendation 5
Primary Hypertension Max C. Reif, M.D.
The following slides highlight a report by Dr
Pharmacological Treatment of Hypertension Update 2012
Hypertension Implementing NICE guidance 2 nd Edition March 2013 NICE clinical guideline 127.
Recommendations for the treatment of confirmed hypertension in people with diabetes. *An ACE inhibitor (ACEi) or angiotensin receptor blocker (ARB) is.
Presentation transcript:

Assessment, Targets, Thresholds and Treatment Bryan Williams NICE clinical guideline 127

Blood Pressure Thresholds for Diagnosis and Treatment of Hypertension Stage of Hypertension Office BP (mmHg) 24hr. Daytime ABPM Average Home ABPM Average Stage 1 Hypertension ≥140 /90 but <160/100 ≥135/85 Stage 2 Hypertension ≥160 / 100≥150/95 Severe Hypertension ≥180/110 Accelerated Hypertension Usually ≥180/110 + retinal haemorrhages and/or papilloedema

Thresholds for Diagnosis and Treatment of Hypertension Stage 1 Hypertension Target organ Damage, CVD, or 10yr CVD risk ≥20% ? YES = Treat No = Lifestyle and review 1 yr.* *for people aged <40ys, 10yr CVD risk assessments underestimate lifetime risk – consider referral for exclusion of secondary causes and more detailed assessment of TOD Stage 2 Hypertension Treat

Thresholds for Diagnosis and Treatment of Hypertension Severe Hypertension Accelerated Hypertension Treat do not wait for ABPM confirmation if TOD or CVD Refer Immediately for inpatient specialist care

Blood Pressure Treatment Targets Use Clinic BP to monitor BP control; Optimal Clinic BP control is <140/90mmHg; In people with “white coat effect”, i.e. clinic BP is ≥20/10mmHg more than ABPM or Home average, use Home BP average to monitor treatment – target home BP average of <135/85mmHg; Review BP control at least annually once BP treatment is stable.

BP Treatment in the very elderly, i.e. aged over 80yrs New evidence suggests that BP lowering reduces the risk of stroke, heart failure and death in people aged over 80yrs; Offer people aged >80yrs same treatment as people aged >55yrs, taking account of co-morbidities; Initiate therapy in people aged > 80yrs at stage 2 hypertension; Treat to a target of <150/90mmHg.

Pharmacological Treatment of Hypertension – Update 2011

Treatment Recommendations – General Concepts Prescribe non-proprietary drugs appropriate, where these are appropriate and minimise cost. [2004] Offer people with isolated systolic hypertension (systolic BP 160 mmHg or more) the same treatment as people with both raised systolic and diastolic blood pressure. [2004] Offer people older than 80 years the same antihypertensive treatment as people aged 55–80 years, taking into account any comorbidities. [new 2011]

Step 1 Treatment Recommendations Offer step 1 antihypertensive treatment with an ACE inhibitor or a low cost ARB to people aged under 55 years. If an ACE inhibitor is used and not tolerated, offer an ARB. [new 2011] Do not combine an ACE inhibitor with an ARB to treat hypertension. [new 2011] Offer step 1 antihypertensive treatment with a CCB to people aged 55 years and older and to Black people of African and Caribbean descent of any age. If a CCB is not suitable, for example because of oedema or intolerance, or if there is evidence of heart failure, or a high risk of heart failure, offer a thiazide-like diuretic. [new 2011]

Why is a CCB Preferred to Diuretic? CCB (usually amlodipine) was the most cost- effective treatment option for treating hypertension unless the patient had heart failure or was at high risk of developing heart failure – i.e. older patient ≥75yrs; CCB is metabolically neutral – easy to use; CCB is best at reducing blood pressure variability and BP variability is an independent predictor of clinical outcomes - especially stroke; At step 2, the combination of A + C was superior to A + D at preventing clinical outcomes.

Treatment Recommendations – Choice of Diuretic Which diuretic ? If a diuretic is required, choose a thiazide- like diuretic, such as chlortalidone (12.5 mg–25.0mg once daily) or indapamide (1.5mg SR, or 2.5 mg once daily) in preference to a conventional thiazide diuretic such as bendroflumethiazide or hydrochlorthiazide. [new 2011]

Why Change the Diuretic ? No need to change diuretic in people stable on treatment and in whom BP is controlled; Evidence review found no evidence in clinical outcome trials of benefits with bendroflumethiazide 2.5mg daily; Most recent trials showing benefits with lower dose diuretics have used thiazide-like diuretics, eg. Indapamide or chlortalidone

Step 2 Treatment Recommendations If step 2 antihypertensive treatment is required, offer a CCB in combination with either an ACE Inhibitor or an ARB. If a CCB is not suitable, for example because of oedema or intolerance, or if there is evidence of heart failure or a high risk of heart failure, offer a thiazide-like diuretic [new 2011]

Step 3 Treatment Recommendations If treatment with three drugs is required, the combination of ACE inhibitor or an ARB, a CCB and a thiazide-like diuretic should be used. [2006]

Step 4 Treatment Recommendations RESISTANT HYPERTENSION Regard clinic blood pressure that remains higher than 140/90 mmHg with the optimal or best tolerated doses of an ACE inhibitor or angiotensin-II receptor blocker plus a calcium channel blocker plus a diuretic as resistant hypertension and consider adding a fourth antihypertensive drug and/or seeking expert advice. [new 2011]

Step 4 Treatment Recommendations RESISTANT HYPERTENSION For treatment of resistant hypertension at step 4, consider further diuretic therapy with low-dose spironolactone (25 mg once daily) if blood potassium levels are lower than 4.5 mmol/l. Caution is required in patients with impaired renal function who are at higher risk of developing hyperkalaemia. If blood potassium levels are higher than 4.5 mmol/l, consider therapy with a higher-dose thiazide-like diuretic treatment.[new 2011] When using further diuretic therapy for resistant hypertension at step 4, monitor blood sodium and potassium and renal function within 1 month and repeat as required thereafter. [new 2011]

Step 4 Treatment Recommendations RESISTANT HYPERTENSION If further diuretic therapy for resistant hypertension at step 4 is not tolerated, contraindicated or ineffective, consider an alpha- or beta-blocker. [new 2011] If blood pressure remains uncontrolled with the optimal or maximum tolerated doses of four drugs, seek expert advice if it has not yet been obtained.[new 2011]

Antihypertensive Drug Treatment Aged <55yrs Aged ≥55yrs or Black AC Step 1 A C* A + C* A + C* + D A + C* + D + Further Diuretic + Consider specialist Advice Step 2 Step 3 Step 4 Resistant Hypertension A = ACEi or ARB C = CCB D = Thiazide-like diuretic C* = CCB preferred but D is an alternative in people intolerant of C or at high risk of heart failure Further Diuretic: Consider low dose spironolactine or higher dose thiazide